High-Dose Chemotherapy for Breast Cancer
Authors: William J. Gradishar
Journal: Annals of Internal Medicine (1997)

Letters1 June 1997High-Dose Chemotherapy for Breast CancerWilliam J. Gradishar, MD and Martin S. Tallman, MDWilliam J. Gradishar, MDNorthwestern University, Chicago, IL 60611Search for more papers by this author and Martin S. Tallman, MDNorthwestern University, Chicago, IL 60611Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-126-11-199706010-00023 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:We appreciate the correspondence from Dr. Rushing and de Vries and colleagues. We understand Dr. Rushing's point that some physicians believe that there is adequate evidence from phase II trials to justify the use of a new therapy without confirmation from a phase III randomized trial comparing the current standard therapy to the new treatment. However, we believe it is premature to assume that high-dose chemotherapy is superior to conventional-dose chemotherapy for women with high-risk early-stage breast cancer, despite the encouraging preliminary data cited by Peters and colleagues [1]. Few long-term outcome data (survival) or toxicity data for ...References1. Peters WP, Ross M, Vredenburgh JJ, Hussein A, Rubin P, Elkordy M. Five-year follow-up of high-dose combination alkylating agents with autologous bone marrow transplantation as consolidation after standard-dose cyclophosphamide, doxorubicin and fluorouracil for primary breast cancer involving ≥ 10 axillary lymph nodes (Duke/CALGB 8782) [Abstract]. Proceedings of the American Society of Clinical Oncology. 1995; 14:317. Google Scholar2. Darrington DL, Vose JM, Anderson JR, Bierman PJ, Bishop MR, Chan WC, et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol. 1994; 12:2527-34. Google Scholar3. Stone RM, Neuberg D, Soiffer R, Takvorian T, Whelan M, Rabinowe SN, et al. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 1994; 12:2535-42. Google Scholar4. Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU, et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol. 1996; 14:2197-205. Google Scholar5. Grever M, Kopecky K, Foucar MK, Head D, Bennett JM, Hutchinson RE, et al. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an Intergroup study. J Clin Oncol. 1995; 13:974-82. Google Scholar Author, Article, and Disclosure InformationAffiliations: Northwestern University, Chicago, IL 60611 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 June 1997Volume 126, Issue 11Page: 918KeywordsBreast cancerChemotherapyDisease free survivalHigh-dose chemotherapyLeukemiaRandomized trialsStem cell transplantationTesticular cancerToxicity Issue Published: 1 June 1997 Copyright & PermissionsCopyright © 1997 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...